Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC).
Eric Pujade-Lauraine
No relevant relationships to disclose
Beatrice E. Weber
No relevant relationships to disclose
Isabelle Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Research Funding - PharmaMar; Roche
Ignace Vergote
Consultant or Advisory Role - Boehringer Ingelheim
Frédéric Selle
No relevant relationships to disclose
Jose Maria Del Campo
No relevant relationships to disclose
Jozef Sufliarsky
Research Funding - Boehringer Ingelheim
Inga Tschöpe
Employment or Leadership Position - Boehringer Ingelheim
Pilar Garin Chesa
Employment or Leadership Position - Boehringer Ingelheim
Serge Nazabadioko
Employment or Leadership Position - Boehringer Ingelheim
Korinna Pilz
Employment or Leadership Position - Boehringer Ingelheim
Florence Joly
Consultant or Advisory Role - PharmaMar; Roche
Honoraria - PharmaMar; Roche